SML1497
Canrenone
≥97% (HPLC), mineralocorticoid inhibitor, powder
别名:
(17α)-17-Hydroxy-3-oxopregna-4,6-diene-21-carboxylic acid γ-lactone, NSC 261713
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H28O3
化学文摘社编号:
分子量:
340.46
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
Canrenone, ≥97% (HPLC)
SMILES string
C[C@@]12C(C=C[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]45OC(CC5)=O)=CC(CC1)=O
InChI key
UJVLDDZCTMKXJK-WNHSNXHDSA-N
InChI
1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1
assay
≥97% (HPLC)
form
powder
optical activity
[α]/D +17 to +24°, c = 1 in chloroform-d
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
room temp
Quality Level
Gene Information
human ... NR3C2(4306)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Canrenone is a mineralocorticoid (aldosterone) inhibitor.
Canrenone is a mineralocorticoid (aldosterone) inhibitor. Aldosterone is known to be involved in hypertension, kidney disease, atherosclerosis, and heart failure. Blockade of the aldosterone receptor has been shown to improve cardiovascular function. In congestive heart failure, aldosterone antagonists are used in addition to other drugs for additive diuretic effect, which reduces edema and the cardiac workload.
Canrenone is an active metabolite of spironolactone with potassium-sparing diuretic activity. Canrenone specifically antagonizes aldosterone at the mineralocorticoid receptor in the kidneys, thereby increasing sodium excretion and inhibiting potassium excretion. It is known to reduce the inflammatory reaction influenced by aldosterone.
Canrenone is an active metabolite of spironolactone with potassium-sparing diuretic activity. Canrenone specifically antagonizes aldosterone at the mineralocorticoid receptor in the kidneys, thereby increasing sodium excretion and inhibiting potassium excretion. It is known to reduce the inflammatory reaction influenced by aldosterone.
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 2 - Carc. 2 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Decio Armanini et al.
Expert opinion on pharmacotherapy, 15(7), 909-912 (2014-03-13)
Canrenone is a derivative of spironolactone with lower antiandrogen activity. The drug is used only in few countries and can block all the side effects of aldosterone (ALDO). The drug is effective even in the presence of normal concentrations of
Li-jun Hu et al.
British journal of clinical pharmacology, 75(5), 1202-1212 (2012-10-24)
Aldosterone antagonists (AldoAs) have been used to treat severe chronic heart failure (CHF). There is uncertainty regarding the efficacy of using AldoAs in mild to moderate CHF with New York Heart Association (NYHA) classifications of I to II. This study
Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
StEiMER W E R N E R, et al.
Clinical Chemistry, 48(3), 507-516 (2002)
Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.
Armanini D, et al.
Expert Opinion on Pharmacotherapy, 15, 909-912 (2014)
Giuseppe Derosa et al.
Annals of medicine, 47(1), 47-52 (2014-10-17)
To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome. A total of 156 Caucasian patients were treated with placebo or canrenone
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持